The field of tumor immunotherapy is evolving rapidly. Many promising areas are discussed in depth in various chapters in this book. This chapter provides a broad overview of additional approaches not covered in specific book chapters. Some areas are nonetheless quite advanced, such as the use of TLR agonists in clinical trials, and some have received FDA approvals such as BCG to treat bladder cancer and the IMiD lenalidomide to treat multiple myeloma. Other areas are of great interest but lack sufficient information to require a dedicated chapter. These miscellaneous areas hold great promise to further the development of effective cancer immunotherapies.
|Original language||English (US)|
|Title of host publication||Cancer Immunotherapy: Paradigms, Practice and Promise|
|Publisher||Springer New York|
|Number of pages||26|
|ISBN (Print)||9781461447320, 1461447313, 9781461447313|
|State||Published - May 1 2013|
ASJC Scopus subject areas